References
Canani LH, Araki S, Warram JH, Krolewski AS (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in Type II diabetes. Diabetologia 44:1062–1069
Heesom AE, Hibberd ML, Millward BA et al. (1997) Polymorphism in the 5′-end of the aldose reductase is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 46:287–291
Sanghera DK, Saha N, Aston CE, Kamboh I (1997) Genetic Polymorphism of the Paraoxonase and the Risk of Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 17:1067–1073
Sanghera DK, Aston CE, Saha N, Kamboh I (1998) DNA Polymorphisms in Two Paraoxonase genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart Disease. Am J Hum Genet 62:36–44
Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in Type II diabetes. Diabetologia 44:104–107
Araki S, Makita Y, Canani L, Ng D, Warram JH, Krolewski AS (2000) Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in Type I diabetes mellitus. Diabetologia 43:1540–1543
Jenkins AJ, Klein RL, Zheng D et al. (2000) Paraoxonase genotype (192 Gln-Arg) and serum paraoxonase-arylesterase activity: Relationship with Type 1 diabetes and nephropathy. Diabetes 49 [Suppl 1]:A157 (Abstract)
Ruiz J, Blanche H, James RW, Garin MC et al. (1995) Gln-Arg192 polymorphisms of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:856
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hodgkinson, A.D., Millward, B.A. & Demaine, A.G. Comment. Diabetologia 45, 933–935 (2002). https://doi.org/10.1007/s00125-002-0838-1
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-002-0838-1